Intranasal Ketamine for Late-Life Depression and Suicidal Ideation
The investigators of this study plan to investigate the feasibility and efficacy of repeated doses of intranasal ketamine in severely depressed patients who are at least 65 years of age and experiencing suicidal ideation. The results of the study could lead to development of new strategies for treating depression.
Details
Randomized, parallel-group, Phase IV trial planned to evaluate feasibility and efficacy of repeated intranasal ketamine (50 mg, six administrations over three weeks) in adults aged 65+ with major depressive disorder and persistent suicidal ideation.
Key eligibility required HDRS28 ≥20, ≥2 failed antidepressant trials in the current episode, and suicidal ideation >2 months; major exclusions included dementia, unstable medical or significant cardiac disease, psychotic disorders, active substance use disorder, and recent ketamine abuse.